ViiV Healthcare, a worldwide specialist HIV company that is majority owned by GSK and has Shionogi Limited and Pfizer Inc. as shareholders, recently lengthened its overall country coverage license for dolutegravir.
The Committee for Medicinal Products for Human Use (CHMP), part of the European Medicines Agency (EMA), recently approved of a new antiseptic gel that can be used to treat newborn umbilical cord infections in developing nations.
The Leukemia and Lymphoma Society (LLS), Patient Power and MDS Alliance have developed a partnership for the first annual AML (acute myeloid leukemia) Awareness Day, designed to increase awareness of the disease.
Leaders at AstraZeneca, and Eli Lilly and Company recently stated that Amaranth, which is a phase II/III study concerning AZD3293 for early Alzheimer’s disease, is scheduled to continue according to plan.
Researchers at the Centers for Disease Control and Prevention (CDC) recently published data taken from the organization’s National Youth Tobacco Survey, showing that the health industry needs to take drastic action against unregulated tobacco products.
AbbVie, a worldwide biopharmaceutical company, recently announced that its new Viekirax plus Exviera treatment has shown positive results regardless of any resistance-associated variants that genotype 1 chronic hepatitis C patients have experienced before the treatments.
Officials at the American Heart Association (AHA) have partnered with Queen Latifah and her mom, Rita Owens, for a second year to encourage Americans who live with heart failure (HF) to rise above the condition.
Shire plc recently submitted a New Drug Application (NDA) for a novel formula of Vyvanse, which would allow the company to make CII into chewable tablets, to the U.S. Food and Drug Administration (FDA).
The American Academy of Family Physicians (AAFP) recently announced that it intends to launch its biggest initiative yet aimed at improving the way primary care is given and how payments are given to U.S. primary care physicians.
A new analysis was recently published to demonstrate that there are relatively few patients with chronic obstructive pulmonary disease who may gain benefits from adding inhaled corticosteroid treatments to their regimens.
The U.S. Food and Drug Administration recently took action to speed the approval of AbbVie’s Venclexta tablets, which is the world’s first BCL-2 inhibitor for relapsed/refractory chronic lymphocytic leukemia patients who have 17p deletion.
Biogen is scheduled to present its latest data, which shows the company’s ability to meet the diverse needs of multiple sclerosis (MS) patients, at the 2016 American Academy of Neurology's annual meeting in Vancouver, Canada.